Click here to close now.

Welcome!

.NET Authors: Carmen Gonzalez, Elizabeth White, Liz McMillan, Greg O'Connor, Jason Bloomberg

News Feed Item

Landauer, Inc. Reports Fiscal 2014 Third Quarter Results

GLENWOOD, Ill., Aug. 4, 2014 /PRNewswire/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and medical consumable accessories, today reported financial results for its fiscal 2014 third quarter ended June 30, 2014.

Fiscal 2014 Third Quarter Highlights

  • Revenue of $34.8 million in the third quarter of fiscal 2014
  • Goodwill and intangible asset impairment charge of $62.2 million related to the carrying value of the Medical Products business
  • Net loss of $36.6 million, or ($3.86) per diluted share, included a total ($6.72) per diluted share of items related to:
    • Goodwill/intangible asset  impairment charge ($6.56 per share), and
    • Acquisition and reorganization costs ($0.16 per share)
  • Adjusted net loss of $0.7 million without the effect of goodwill/intangible asset impairment charges and reorganization costs recorded in the third fiscal quarter of 2014
  • Adjusted EBITDA of $7.4 million
  • Adjusted Free Cash Flow of $7.3 million in the third quarter of fiscal 2014
  • Military order for $14.5 million received for the Radwatch system
  • Updated Financial Guidance:
    • Revenue reaffirmed at a range of $150 million to $160  million
    • Adjusted EBITDA reaffirmed at a range of $44 million to $46 million
    • Adjusted Net Income reaffirmed at a range of $16 million to $18 million without the effect of impairment charges taken in the quarter

"The ongoing challenges we are facing in the market for our Medical Products segment has resulted in the business performing significantly below our expectations.  The business is facing increasingly aggressive competitive pricing challenges for its primary product line which has substantially reduced sales and gross margin.  This has resulted in a non-cash impairment charge that impacted our quarterly financial results.  Despite the issues, we continue to take steps both operationally and from a potential new business perspective to strengthen the long-term viability of this segment, including the planned launch of new products," said Bill Saxelby, President and CEO of Landauer.

"We continue to focus on growing our free cash flow position, which will allow us to invest in future growth opportunities while maintaining dividend distributions to our shareholders. During the quarter, we made strong progress in Radiation Measurement with our next generation dosimetry platform and we recently received a military order for $14.5 million, for the Radwatch system, a portion of which will be recognized in the fiscal fourth quarter directly and with our military partner Aquila. In Medical Physics we signed one new hospital system agreement and see customers begin to implement new imaging regulations underscoring the value of our offering. Medical Products is focused on new medical devices with pending FDA product applications to complement our existing product offering."

Saxelby added, "By leveraging our global leadership in passive occupational dosimetry services and our core competencies in radiation measurement and informatics, Landauer is focused on becoming the leading provider of radiation safety and security solutions that ensure our customers are in compliance with the evolving regulatory requirements landscape. These requirements will help in driving our strategic growth initiatives going forward and will create value for our shareholders."

Third Fiscal Quarter Financial Overview and Business Segment Results

Revenues for the third fiscal quarter of 2014 and for the third fiscal quarter of 2013 were $34.8 million and $36.6 million, respectively. The Radiation Measurement segment revenue decreased $2.2 million primarily due to the timing of Radwatch sales. The decrease was partially offset by an increase in the Medical Physics segment of $0.3 million, or 3.8 percent, compared to the prior year period.  In addition, the Company recorded a $0.9 million adjustment to correct the timing of revenue recognition related to dosimeter wear periods and a $0.5 million adjustment to correct revenue recorded in the second fiscal quarter of 2014.  The amounts recorded out-of-period includes an increase in the pre-tax loss of $1.3 million for the third fiscal quarter ended June 30, 2014.

Gross margins were 48.3 percent for the third fiscal quarter of 2014, compared with 50.9 percent for the third fiscal quarter of 2013. The decrease in the gross margin over the prior year period was due to the decrease in revenues of our Radiation Measurement products as a result of the $0.9 million adjustment to correct the timing of revenue recognition related to dosimeter wear periods and a $0.5 million adjustment to correct revenue recorded in the second fiscal quarter of 2014. 

Total selling, general and administrative expenses for the third fiscal quarter of 2014 and 2013 were $13.8 million and $12.6 million, respectively. For the third fiscal quarter of 2014, total selling, general and administrative expenses increased due to bad debt expense of $0.7 million and professional and consulting fees of $0.5 million.

During the third fiscal quarter of 2014, it became apparent that anticipated revenue and profitability trends in our Medical Products reporting unit were not being achieved to the extent forecasted.  Early budget reviews also indicated future sales growth and margins may be less than expected.  We updated the forecast for our Medical Products operating segment based on the most recent financial results and our best estimates of future operations. The updated forecast reflects slower growth in revenues and lower margins for the Medical Products segment due to anticipated continued pricing pressures from certain competitors. We recorded a $62.2 million pretax charge for the impairment of goodwill and intangible assets to reduce their carrying value in our Medical Products segment. The impairment charge during this period is non-cash in nature and does not affect the Company's current liquidity or debt covenant compliance.

Operating loss for the third fiscal quarter of 2014 was $60.8 million compared with operating loss of $16.8 million for the third fiscal quarter of 2013.  Operating income, adjusted for the impairment charge and reorganization costs (primarily severance costs) recorded during the third fiscal quarter of 2014, was $3.0 million.  Operating income, adjusted for the $22.7 million impairment charge for the third fiscal quarter of 2013, was $5.9 million.

The effective tax rate for the third fiscal quarter of 2014 and 2013 was 40.8 percent and 21.6 percent, respectively. The increase in the effective tax rate was driven by the effect of certain permanent items having a greater impact on our rate due to a lower level of book income. 

Net loss for the third fiscal quarter ended June 30, 2014 was $36.6 million, or $3.86 per diluted share, compared to net loss of $13.8 million, or $1.46 per diluted share, in the same period last year. The decrease in net income was due to the impairment charge of $62.2 million and to $1.6 million of reorganization expenses, partially offset by a larger tax benefit.

Excluding the impairment charge, the adjusted net loss was $0.7 million, compared to adjusted net income of $4.8 million in the comparable prior year period.  The resulting adjusted diluted earnings per share for the third fiscal quarter ended June 30, 2014 was ($0.07) per share, compared to $0.51 in the same period last year.

Adjusted EBITDA for the fiscal third quarter 2014 was $7.4 million compared with $11.1 million for the third fiscal quarter of 2013. The decrease was due primarily to reduced gross margin of $1.8 million, an increase in bad debt expense of $0.7 million, outside services of $0.5 million along with a decrease in equity income of joint ventures of $0.2 million due to the timing of military orders. A reconciliation of net income to EBITDA and Adjusted EBITDA is included in the attached financial exhibits.

Change in Segment Presentation

During the first fiscal quarter of 2014, the Company changed the presentation of its reporting segments to separately disclose certain 'corporate expenses' that had previously been reported within the Radiation Measurement segment.  As a result, the current segment disclosures will reflect three reporting segments: Radiation Measurement, Medical Physics, Medical Products and one functional group, Corporate.

Radiation Measurement Segment

Radiation Measurement revenues for the third fiscal quarter of 2014 were $24.2 million, a decrease of 8.3 percent, or $2.2 million from the third fiscal quarter of 2013 of $26.4 million. The decrease in the fiscal 2014 third quarter was due primarily to lower Radwatch revenues of $1.3 million, driven by the timing of military orders.  In addition, the Company recorded an adjustment to revenue of $0.9 million to correct the dosimeter wear periods used to compute service revenue and a $0.5 million adjustment to correct revenue recorded in the second fiscal quarter of 2014.

Radiation Measurement operating income for the third fiscal quarter of 2014 decreased to $6.3 million, or 27.6 percent, from $8.7 million in the comparable prior year period.  The decrease in operating income was due to a $1.4 million decrease in gross margin resulting from the decrease in revenues as well as a $1.1 million increase in selling, general and administrative expenses due to higher bad debt expense and consulting fees.

Medical Physics Segment

Medical Physics revenues for the third fiscal quarter of 2014 increased 3.8 percent to $8.2 million, as compared to $7.9 million in the third fiscal quarter of 2013. Medical Physics operating income was $0.4 million as compared to $1.0 million the third fiscal quarter of 2013. The decrease in operating income was primarily due to increased staffing expenses of $0.7 million to support additional contracts in the imaging division and to support the continued advancement of the segment's system-sell initiatives.

Medical Products Segment        

Medical Products revenues for the third fiscal quarter of 2014 were $2.4 million, an increase of $0.1 million or 4.3 percent, compared to $2.3 million for the third fiscal quarter of 2013. Medical Products operating loss for the third fiscal quarter of 2014 was $62.4 million as compared to an operating loss of $22.6 million for the third fiscal quarter of 2013. The decrease in operating income was due primarily to the goodwill/intangible impairment of $62.2 million compared to a $22.7 million goodwill impairment charge in the same period in fiscal 2013.

Corporate Selling, General and Administrative Expenses

Corporate selling, general and administrative expenses reflect costs associated with supporting the entire Company, including executive management and administrative functions such as accounting, treasury, legal, human resources, and information technology management, as well as other costs required to support the Company.  Corporate expenses for the third fiscal quarter of 2014 were $5.1 million, an increase of $1.2 million as compared to $3.9 million in the third fiscal quarter of 2013.  The increase was due primarily to reorganization costs, primarily severance, recorded during the third fiscal quarter of 2014.

Fiscal Nine Months Financial Overview and Business Segment Results

Revenues for the first nine months of fiscal 2014 were $112.0 million, an increase of $1.7 million, or 1.4 percent compared with revenues of $110.3 million for the same period in fiscal 2013.  The Radiation Measurement segment had a revenue increase of $1.1 million and the Medical Physics segment had a revenue increase of $0.9 million.  The Medical Products segment revenue declined $0.3 million.

The first nine months of fiscal 2014 included the correction of certain errors relating to prior periods. The amounts recorded out-of-period include an increase in the pre-tax loss of $0.9 million for nine month period ended June 30, 2014.

Gross margins were 51.3 percent for the first nine months of fiscal 2014, compared with 53.3 percent for the first nine months of fiscal 2013.  The decline in gross margin over the prior year period was due to increased labor to support additional contracts in the Medical Physics imaging division.

Total selling, general and administrative expenses for the first nine months of fiscal 2014 were $41.9 million, an increase of $3.4 million, or 8.8 percent, compared to $38.5 million for the first nine months of fiscal 2013. For the first nine months of fiscal 2014, total selling, general and administrative expenses included increased research and development expenses of $2.1 million related to the Company's next generation dosimetry platform.  In addition, the increase was due to higher bad debt expense of $0.8 million and higher professional fees and outside services of $0.7 million.

Operating loss for the first nine months of fiscal 2014 was $48.4 million compared with operating loss of $2.9 million for the same period in fiscal 2013.  The higher loss was due primarily to an increase in goodwill and intangible assets impairments as well as reorganization costs.

The effective tax rate was an expense of 43.4 percent and a benefit of (4.6 percent), for the first nine months of fiscal 2014 and 2013, respectively.  The increase in the effective tax rate was driven by the effect of certain permanent items having a greater impact on our rate due to a lower level of book income.  Without impairment of intangibles the effective tax rate for the first nine months of fiscal 2014 would have been 27.8 percent.

As a result, net loss for the first nine months of fiscal 2014 of $28.6 million, compared to $3.7 million in the same period in fiscal 2013, primarily due to the impairment charge of $62.2 million.

Adjusted EBITDA for the first nine months of fiscal 2014 was $28.9 million compared with $35.4 million for the first nine months of fiscal 2013. The decrease was due primarily to reduced gross margin of $1.2 million, an increase in research and development expenses of $2.1 million, bad debt expense of $0.8 million, outside services of $0.7 million along with a decrease in equity income of joint ventures of $1.2 million due to the timing of military orders. A reconciliation of net income to EBITDA and Adjusted EBITDA is included in the attached financial exhibits.

Radiation Measurement Segment

Radiation Measurement revenues for the first nine months of fiscal 2014 were $81.1 million, an increase of $1.1 million, or 1.4%, from the first nine months of fiscal 2013 of $80.0 million. The increase in the first nine months of fiscal 2013 was primarily due to increases in revenues at international subsidiaries of $2.6 million, partially offset by a decrease in Radwatch revenues of $1.0 million, driven by the timing of military orders.  In addition, the Company recorded an adjustment to revenue of $0.9 million to correct the dosimeter wear periods used to compute service revenue.  

Radiation Measurement operating income for the third fiscal quarter of 2014 decreased to $25.2 million, or 11.0 percent, from $28.3 million in the comparable prior year period.  The decrease in operating income was due to increased research and development expenses of $2.1 million for the advancement of the Company's next generation dosimeter, as well as higher bad debt expense and professional fees.

Medical Physics Segment

Medical Physics revenues for the first nine months of fiscal 2014 were $23.9 million, an increase of $0.8 million, or 3.5%, as compared to $23.1 million for the first nine months of fiscal 2013.  Medical Physics operating income for the first nine months of fiscal 2014 was $1.5 million as compared to $2.6 million in the first nine months of fiscal 2013.  The decrease in operating income was primarily due to increased staffing expenses of $0.7 million to support additional contracts in the imaging division and to support the continued advancement of the segment's system-sell initiatives.

Medical Products Segment

Medical Products revenues for the first nine months of fiscal 2014 were $6.9 million, a decrease of $0.3 million, or 4.2%, compared to $7.2 million for the first nine months of fiscal 2013. The decrease in revenues of $0.3 million is due primarily to the decline in the Spherz selling price and shipments.   Medical Products operating loss for the first nine months of fiscal 2014 was $63.0 million as compared to $21.6 million in the first nine months of fiscal 2013.  The increase in operating loss was due to the impairment charge of $62.2 million.

Corporate Selling, General and Administrative Expenses

Corporate selling, general and administrative expenses reflect costs associated with supporting the entire Company, including executive management and administrative functions such as accounting, treasury, legal, human resources, and information technology management, as well as other costs required to support the Company.  Corporate expenses were essentially flat at $12.1 million for the first nine months of fiscal 2014 and 2013.    

Balance Sheet, Liquidity and Capital Resources

Landauer ended the third fiscal quarter of 2014 with total assets of $222.7 million, compared to total assets of $276.8 million at the end of fiscal 2013, a decrease of $54.1 million, of which $62.2 million was related to the goodwill and intangible assets impairment charge.  The Company completed the quarter with $11.2 million of cash and cash equivalents on the balance sheet and unused borrowing capacity of $36.7 million under its $175 million credit facility, which provides adequate liquidity to meet its current and anticipated obligations. 

Adjusted free cash flow for the first nine months of fiscal 2014 was $25.2 million, an increase of $13.4 million over the same fiscal period in 2013. 

Fiscal 2014 Outlook

Saxelby concluded, "As we move into the fourth quarter, we are reaffirming our previous guidance excluding the impact of the charges in the third quarter. We feel positively about the underlying strength of the Radiation Measurement and Medical Physics segments and are working to improve our Medical Products business."

Landauer's business plan for fiscal 2014 currently anticipates aggregate revenues for the year to be in the range of $150 to $160 million, and reflects the uncertainty of government funding during fiscal 2014 for the military equipment sales opportunities the company has developed.  The business plan also anticipates:

  • The effective tax rate for the full fiscal year is anticipated to be within a range of 42 percent to 45 percent. Excluding the impact of the goodwill and intangible assets impairment, the effective tax rate would range from 25 percent to 30 percent.
  • Based upon the above assumptions, the Company anticipates Adjusted Net Income for fiscal 2014 in the range of $16 to $18 million, and Adjusted EBITDA for fiscal 2014 in the range of $44 to $46 million.

Conference Call Details

Landauer has scheduled its third quarter conference call for investors over the Internet on Tuesday, August 5, 2014, at 9:00 a.m. Central Time (10 a.m. Eastern Time).  To participate, callers should dial 888-438-5491 (within the United States and Canada), or 719-325-2177 (international callers) about 10 minutes before the presentation.  To listen to a webcast on the Internet, please go to the Company's website at http://www.landauer.com at least 15 minutes early to register, download and install any necessary audio software.  Investors may access a replay of the call by dialing 888-203-1112 (within the United States and Canada), or 719-457-0820 (international callers), passcode 9933551, which will be available through Thursday, September 4, 2014.  The replay will also be available on Landauer's website for 90 days following the call.

About Landauer

Landauer is a leading global provider of technical and analytical services to determine occupational and environmental radiation exposure, the leading domestic provider of outsourced medical physics services, as well as a provider of high quality medical accessories used in radiology, radiation therapy, and image guided surgery procedures.  For more than 50 years, the Company has provided complete radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries in which radiation poses a potential threat to employees.  Landauer's services include the manufacture of various types of radiation detection monitors, the distribution and collection of the monitors to and from customers, and the analysis and reporting of exposure findings.  The Company provides its dosimetry services to approximately 1.8 million individuals globally.  In addition, through its Medical Physics segment, the Company provides therapeutic and imaging physics services to the medical physics community. Through its Medical Products segment, the Company provides medical consumable accessories used in radiology, radiation therapy, and image guided surgery procedures.  For information about Landauer, please visit their website at http://www.landauer.com.

Safe Harbor Statement

Some of the information shared here (including, in particular, the section titled "Fiscal 2014 Outlook") constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties.  These include the following, without limitation: assumptions, risks and uncertainties associated with the Company's future performance, the Company's development and introduction of new technologies in general; the ability to protect and utilize the Company's intellectual property; events or circumstances which result in an impairment of assets, including but not limited to, goodwill and identifiable intangible assets; continued customer acceptance of the InLight technology; the adaptability of optically stimulated luminescence (OSL) technology to new platforms and formats; military and other government funding for the purchase of certain of the Company's equipment and services; the impact on sales and pricing of certain customer group purchasing arrangements; changes in spending or reimbursement for medical products or services; the costs associated with the Company's research and business development efforts; the usefulness of older technologies and related licenses and intellectual property; the effectiveness of and costs associated with the Company's IT platform enhancements; the anticipated results of operations of the Company and its subsidiaries or ventures; valuation of the Company's long-lived assets or business units relative to future cash flows; changes in pricing of products and services; changes in postal and delivery practices; the Company's business plans; anticipated revenue and cost growth; the ability to integrate the operations of acquired businesses and to realize the expected benefits of acquisitions; the risks associated with conducting business internationally; costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing economic and competitive conditions, including instability in capital markets which could impact availability of short and long-term financing; the timing and extent of changes in interest rates; the level of borrowings; foreign exchange rates; government regulations; accreditation requirements; changes in the trading market that affect the costs of obligations under the Company's benefit plans; and pending accounting pronouncements.  These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from what is anticipated today.  These risks and uncertainties also may result in changes to the Company's business plans and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to incur unanticipated expenses.  Additional information may be obtained by reviewing the information set forth in Item 1A "Risk Factors" and Item 7A "Quantitative and Qualitative Disclosures about Market Risk" and information contained in the Company's Annual Report on Form 10-K for the year ended September 30, 2013 and other reports filed by the Company, from time to time, with the Securities and Exchange Commission.  The Company does not undertake, and expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future events or changes in the Company's expectations, except as required by law.

Financial Tables Follow


Landauer, Inc. and Subsidiaries

Consolidated Balance Sheets








(Dollars in Thousands)


June 30,
2014


September 30,
2013

ASSETS







Current assets:







Cash and cash equivalents


$

11,154


$

11,184

Receivables, net of allowances of $1,030 and $600 respectively



34,750



38,419

Inventories



7,734



9,539

Prepaid expenses and other current assets



11,688



7,151

Current assets



65,326



66,293

Net property, plant and equipment



48,392



51,932

Equity in joint ventures



23,744



23,942

Goodwill



44,645



84,436

Intangible assets, net of accumulated amortization of $37,543 and $13,604, respectively



14,663



37,161

Other assets



25,948



13,069

Assets


$

222,718


$

276,833

LIABILITIES AND STOCKHOLDERS' EQUITY







Current liabilities



42,388



40,648

Non-current liabilities:







Long-term debt



138,285



142,785

Other non-current liabilities



15,662



23,779

Non-current liabilities



153,947



166,564

Stockholders' equity



26,383



69,621

Liabilities and Stockholders' Equity


$

222,718


$

276,833

 

Landauer, Inc. and Subsidiaries

Third Fiscal Quarter 2014 Financial Highlights

















Three Months Ended
June 30,



Nine Months Ended
June 30,

(Dollars in Thousands, Except per Share)


2014


2013


2014


2013

Net revenues


$

34,766


$

36,580


$

112,025


$

110,343














Cost of sales



17,979



17,964



54,531



51,577

Selling, general and administrative



13,805



12,550



41,902



38,519

Goodwill and other intangible impairment charge



62,188



22,700



62,188



22,700

Acquisition and reorganization costs



1,558



142



1,778



442

Costs and expenses



95,530



53,356



160,399



113,238

Operating loss



(60,764)



(16,776)



(48,374)



(2,895)

Equity in income of joint ventures



256



471



1,364



2,555

Other loss, net



(839)



(1,042)



(2,677)



(2,837)

Loss before taxes



(61,347)



(17,347)



(49,687)



(3,177)

Income tax (benefit) expense



(25,030)



(3,748)



(21,580)



146

Net loss



(36,317)



(13,599)



(28,107)



(3,323)

Less:  Net income attributed to noncontrolling interest



309



154



471



400

Net loss attributed to Landauer, Inc.


$

(36,626)


$

(13,753)


$

(28,578)


$

(3,723)

Net loss per share attributable to Landauer, Inc. shareholders:













Basic & diluted


$

(3.86)


$

(1.46)


$

(3.02)


$

(0.40)

Weighted average shares outstanding - basic & diluted



9,482



9,439



9,466



9,402

 

Landauer, Inc. and Subsidiaries

Consolidated Statements of Cash Flows









Nine Months Ended
June 30,

(Dollars in Thousands)


2014


2013

Cash flows from operating activities:







Net loss


$

(28,107)


$

(3,323)

Adjustments to reconcile net income to net cash provided by operating activities:







Depreciation and amortization



11,607



10,860

Goodwill and other intangible impairment charge



62,188



22,700

Equity in  income of joint ventures



(1,365)



(2,555)

Dividends from joint ventures



1,340



1,891

Stock-based compensation and related net tax benefits



1,066



2,293

Current and long-term deferred taxes, net



(21,973)



(5,531)

Gain on sale, disposal and abandonment of fixed assets



(35)



-

Gain on investments



(369)



-

Changes in operating assets and liabilities



2,329



(6,753)

Net cash provided by operating activities



26,681



19,582

Net cash used by investing activities



(5,893)



(10,108)

Cash flows used  by financing activities:







Long-term (repayment) borrowings



(4,500)



(1,787)

Dividends paid to stockholders



(15,771)



(15,658)

Other financing activities, net



(551)



(460)

Net cash used by financing activities



(20,822)



(17,905)

Effects of foreign currency translation



4



(205)

Net decrease in cash and cash equivalents



(30)



(8,636)

Opening balance - cash and cash equivalents



11,184



17,633

Ending balance - cash and cash equivalents


$

11,154


$

8,997

 

A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is provided below:





















Three Months Ended
June 30,

Nine Months Ended
June 30,


2014


2013

2014


2013

Adjusted EBITDA











Net (Loss) income attributed to Landauer, Inc.

$

(36,626)


$

(13,753)

$

(28,578)


$

(3,723)

Add back:











Interest expense, net


711



1,049


2,373



2,957

Depreciation and amortization


3,945



3,884


11,607



10,860

Provision for income taxes


(25,030)



(3,748)


(21,580)



146

Earnings before interest, taxes, depreciation
and amortization (EBITDA)

$

(57,000)


$

(12,568)

$

(36,178)


$

10,240

Adjustments:











Non-cash stock based compensation


616



789


1,079



1,855

IT platform enhancements expenses


-



1


-



206

Acquisition and reorganization costs


1,558



142


1,778



442

Goodwill and other intangible impairment charge


62,188



22,700


62,188



22,700

Sub-total adjustments


64,362



23,632


65,045



25,203

Adjusted EBITDA

$

7,362


$

11,064

$

28,867


$

35,443













Three Months Ended
June 30,

Nine Months Ended
June 30,


2014


2013

2014


2013

Adjusted Net Income











Net loss attributed to Landauer, Inc.

$

(36,626)


$

(13,753)

$

(28,578)


$

(3,723)

Sub-total adjustments


64,362



23,632


65,045



25,203

Income-taxes on adjustments


(28,432)



(5,105)


(28,230)



1,159

Adjustments, net


35,930



18,527


36,815



26,362

Adjusted, Net (Loss) Income

$

(696)


$

4,774

$

8,237


$

22,639

Adjusted Net (Loss) Income per Diluted Share

$

(0.07)


$

0.51

$

0.87


$

2.41

 














Nine Months Ended
June 30,

Free Cash Flow

2014


2013

Net cash provided by operating activities

$

26,681


$

19,582

Capital expenditures


(3,056)



(8,135)

Free Cash flow


23,625



11,447

IT platform enhancements expenses


-



205

Acquisition and reorganization costs


1,558



142

Adjusted Free Cash Flow

$

25,183


$

11,794

Segment Information

The following tables summarize financial information for each reportable segment for the three and nine months ended June 30: 





























Three Months Ended
June 30,


Nine Months Ended
June 30,



2014


2013


2014


2013

Revenues by segment:













Radiation Measurement


$

24,218


$

26,383


$

81,143


$

80,035

Medical Physics



8,175



7,903



23,943



23,090

Medical Products



2,373



2,294



6,939



7,218

Consolidated revenues


$

34,766


$

36,580


$

112,025


$

110,343
















Three Months Ended
June 30,


Nine Months Ended
June 30,



2014


2013


2014


2013

Operating income (loss) by segment:













Radiation Measurement


$

6,329


$

8,715


$

25,209


$

28,289

Medical Physics



435



1,056



1,468



2,580

Medical Products



(62,429)



(22,591)



(63,041)



(21,617)

Corporate



(5,099)



(3,956)



(12,010)



(12,147)

Consolidated operating loss


$

(60,764)


$

(16,776)


$

(48,374)


$

(2,895)

 

SOURCE Landauer, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
SYS-CON Events announced today the IoT Bootcamp – Jumpstart Your IoT Strategy, being held June 9–10, 2015, in conjunction with 16th Cloud Expo and Internet of @ThingsExpo at the Javits Center in New York City. This is your chance to jumpstart your IoT strategy. Combined with real-world scenarios and use cases, the IoT Bootcamp is not just based on presentations but includes hands-on demos and walkthroughs. We will introduce you to a variety of Do-It-Yourself IoT platforms including Arduino, Raspberry Pi, BeagleBone, Spark and Intel Edison. You will also get an overview of cloud technologies s...
The only place to be June 9-11 is Cloud Expo & @ThingsExpo 2015 East at the Javits Center in New York City. Join us there as delegates from all over the world come to listen to and engage with speakers & sponsors from the leading Cloud Computing, IoT & Big Data companies. Cloud Expo & @ThingsExpo are the leading events covering the booming market of Cloud Computing, IoT & Big Data for the enterprise. Speakers from all over the world will be hand-picked for their ability to explore the economic strategies that utility/cloud computing provides. Whether public, private, or in a hybrid form, clo...
WebRTC is an up-and-coming standard that enables real-time voice and video to be directly embedded into browsers making the browser a primary user interface for communications and collaboration. WebRTC runs in a number of browsers today and is currently supported in over a billion installed browsers globally, across a range of platform OS and devices. Today, organizations that choose to deploy WebRTC applications and use a host machine that supports audio through USB or Bluetooth can use Plantronics products to connect and transit or receive the audio associated with the WebRTC session.
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, will discuss how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at the same time reduce Time to Market (TTM) by using plug and play capabilities offered by a robust I...
IoT is still a vague buzzword for many people. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. He also discussed how IoT is perceived by investors and how venture capitalist access this space. Other topics discussed were barriers to success, what is new, what is old, and what the future may hold. Mike Kavis is Vice President & Principal Cloud Architect at Cloud Technology Pa...
@ThingsExpo has been named the Top 5 Most Influential Internet of Things Brand by Onalytica in the ‘The Internet of Things Landscape 2015: Top 100 Individuals and Brands.' Onalytica analyzed Twitter conversations around the #IoT debate to uncover the most influential brands and individuals driving the conversation. Onalytica captured data from 56,224 users. The PageRank based methodology they use to extract influencers on a particular topic (tweets mentioning #InternetofThings or #IoT in this case) takes into account the number and quality of contextual references that a user receives.
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? Join this panel of experts as they peel away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud environment, and we must architect and code accordingly. At the very least, you’ll have no problem filling in your buzzword bingo cards.
So I guess we’ve officially entered a new era of lean and mean. I say this with the announcement of Ubuntu Snappy Core, “designed for lightweight cloud container hosts running Docker and for smart devices,” according to Canonical. “Snappy Ubuntu Core is the smallest Ubuntu available, designed for security and efficiency in devices or on the cloud.” This first version of Snappy Ubuntu Core features secure app containment and Docker 1.6 (1.5 in main release), is available on public clouds, and for ARM and x86 devices on several IoT boards. It’s a Trend! This announcement comes just as...
SYS-CON Events announced today that AIC, a leading provider of OEM/ODM server and storage solutions, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. AIC is a leading provider of both standard OTS, off-the-shelf, and OEM/ODM server and storage solutions. With expert in-house design capabilities, validation, manufacturing and production, AIC's broad selection of products are highly flexible and are configurable to any form factor or custom configuration. AIC leads the industry with nearly 20 years of ...
Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 16th Cloud Expo at the Javits Center in New York June 9-11 will find fresh new content in a new track called PaaS | Containers & Microservices Containers are not being considered for the first time by the cloud community, but a current era of re-consideration has pushed them to the top of the cloud agenda. With the launch of Docker's initial release in March of 2013, interest was revved up several notches. Then late last...
As enterprises move to all-IP networks and cloud-based applications, communications service providers (CSPs) – facing increased competition from over-the-top providers delivering content via the Internet and independently of CSPs – must be able to offer seamless cloud-based communication and collaboration solutions that can scale for small, midsize, and large enterprises, as well as public sector organizations, in order to keep and grow market share. The latest version of Oracle Communications Unified Communications Suite gives CSPs the capability to do just that. In addition, its integration ...
SYS-CON Events announced today that Creative Business Solutions will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Creative Business Solutions is the top stocking authorized HP Renew Distributor in the U.S. Based out of Long Island, NY, Creative Business Solutions offers a one-stop shop for a diverse range of products including Proliant, Blade and Industry Standard Servers, Networking, Server Options and Care Packs. As a trusted supplier, CBS guarantees quality controlled stock levels thanks to an Auto...
SOA Software has changed its name to Akana. With roots in Web Services and SOA Governance, Akana has established itself as a leader in API Management and is expanding into cloud integration as an alternative to the traditional heavyweight enterprise service bus (ESB). The company recently announced that it achieved more than 90% year-over-year growth. As Akana, the company now addresses the evolution and diversification of SOA, unifying security, management, and DevOps across SOA, APIs, microservices, and more.
GENBAND introduced its Real Time Communications (RTC) Client for Lync* to seamlessly combine real-time communications with Lync Instant Messaging (IM) and Presence. “We’re shaking up the economics of delivering Unified Communications (UC) and offering a compelling way to integrate previously bespoke communications technologies,” said Carl Baptiste, GENBAND’s Senior Vice President, Enterprise Solutions. “We’re offering enterprises the best of both worlds by combining our own high availability voice, video and collaboration with Lync’s IM and Presence; creating a single, web centric, client. O...
After making a doctor’s appointment via your mobile device, you receive a calendar invite. The day of your appointment, you get a reminder with the doctor’s location and contact information. As you enter the doctor’s exam room, the medical team is equipped with the latest tablet containing your medical history – he or she makes real time updates to your medical file. At the end of your visit, you receive an electronic prescription to your preferred pharmacy and can schedule your next appointment.
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, shared some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder of TeleStax, a...
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT.
SYS-CON Events announced today that Optimal Design, an Internet of Things solution provider, will exhibit at SYS-CON's Internet of @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Optimal Design is an award winning product development firm offering industrial design and engineering services to the consumer, medical, and defense markets.
How is unified communications transforming the way businesses operate? In his session at WebRTC Summit, Arvind Rangarajan, Director of Product Marketing at BroadSoft, will discuss how to extend unified communications experience outside the enterprise through WebRTC. He will also review use cases across different industry verticals. Arvind Rangarajan is Director, Product Marketing at BroadSoft. He has over 19 years of experience in the telecommunications industry in various roles such as Software Development, Product Management and Product Marketing, applied across Wireless, Unified Communic...
The list of ‘new paradigm’ technologies that now surrounds us appears to be at an all time high. From cloud computing and Big Data analytics to Bring Your Own Device (BYOD) and the Internet of Things (IoT), today we have to deal with what the industry likes to call ‘paradigm shifts’ at every level of IT. This is disruption; of course, we understand that – change is almost always disruptive.